Compare CEPU & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CEPU | PHVS |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | Argentina | Switzerland |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2017 | 2020 |
| Metric | CEPU | PHVS |
|---|---|---|
| Price | $14.33 | $34.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $17.50 | ★ $41.82 |
| AVG Volume (30 Days) | 250.3K | ★ 566.0K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.43 | $19.12 |
| 52 Week High | $18.50 | $36.60 |
| Indicator | CEPU | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 57.18 |
| Support Level | $13.87 | $24.73 |
| Resistance Level | $16.45 | $36.60 |
| Average True Range (ATR) | 0.57 | 1.64 |
| MACD | -0.04 | -0.14 |
| Stochastic Oscillator | 20.42 | 54.17 |
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.